Clinically, ATRX mutations are strongly associated with younger age, co-occurring IDH and TP53 mutations, and prolonged overall survival, reinforcing their dual prognostic and predictive significance in glioma biology (49). This evidence concerns the gene IDH2 and central nervous system cancer.